Michael Demurjian is the founder, chairman, and CEO of clinical-stage pharmaceutical company, Aspargo Laboratories, Inc.
Aspargo is the developer of an oral spray formulation that serves as an alternative to Viagra® and Cialis®.
In 2011, Demurjian also co-founded Tyme Technologies, Inc., a clinical-stage biotechnology company creating metabolic-based cancer therapeutics designed to be effective across tumor types. While there, Demurjian raised over $50 million and took Tyme public on NASDAQ, holding 70 percent control of the company with his partner, Steve Hoffman.
Prior to Aspargo Labs and Tyme, the biotech leader was CEO of oncology research firm, Luminant Biosciences. He has taken companies both public and private and raised funds via retail and institutional investors, including deals with G.E., Black & Decker Corp., Stryker, and Crane Cams.
Demurjian currently serves on the Susan G. Komen Foundation board of directors and New York University’s board of advisors. Previously, he sat on the boards of KCC Inc., Mikronite Technologies, and Luminant Biosciences.
What is Michael Demurjian's net worth?
The estimated net worth of Michael Demurjian is at least $27.81 million as of July 26th, 2021. Mr. Demurjian owns 24,398,546 shares of Tyme Technologies stock worth more than $27,814,342 as of July 31st. This net worth approximation does not reflect any other assets that Mr. Demurjian may own.
How do I contact Michael Demurjian?
The corporate mailing address for Mr. Demurjian and other Tyme Technologies executives is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. Tyme Technologies can also be reached via phone at 212-461-2315 and via email at [email protected]
Has Michael Demurjian been buying or selling shares of Tyme Technologies?
In the last ninety days, Michael Demurjian has sold $97,800.00 in shares of Tyme Technologies stock. Most recently, Michael Demurjian sold 20,000 shares of the business's stock in a transaction on Monday, July 26th. The shares were sold at an average price of $1.53, for a transaction totalling $30,600.00. Following the completion of the sale, the insider now directly owns 24,398,546 shares of the company's stock, valued at $37,329,775.38.
Are insiders buying or selling shares of Tyme Technologies?
In the last year, Tyme Technologies insiders bought shares 5 times. They purchased a total of 64,258 shares worth mmore than $67,953.43. In the last year, insiders at the sold shares 65 times. They sold a total of 1,933,827 shares worth mmore than $5,201,942.42. The most recent insider tranaction occured on July, 26th when Michael Demurjian Major Shareholder bought 20,000 shares worth more than $30,600.00. Insiders at Tyme Technologies own 16.9 % of the company.
Information on this page was last updated on 7/26/2021.